Logo Image
Commentary|Podcasts|July 11, 2024

The Weight-Loss Gold Rush: Legal and Regulatory Implications

Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.

Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses:

  • Top legal and regulatory concerns for investors considering when financing companies developing or marketing GLP-1 drugs
  • How the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs
  • What needs to be done for GLP-1s to be covered
  • Steps companies developing weight-loss medications should take to ensure responsible and ethical practice
  • Advice for investors and financiers who are considering entering the weight-loss medication market

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Fayuvi
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Read more
Pharmaceutical Executive daily
Pharmaceutical Executive Daily: FDA Approves New Indication for Kerendia
FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon Medical strike major deals and mergers with Orbis Medicines, Dualitas Therapeutics, and North Immunology, and Thani Jambulingam of Saint Joseph's University examines the fight to control the GLP-1 patient journey.
Read more
Pharmaceutical executive daily
Pharmaceutical Executive Daily: Sanofi & Cheplapharm Form Strategic Partnership
GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why pharma marketing now has to write for both people and AI, and Dr. Elena Christofides explains why cortisol dysregulation may be the hidden reason some diabetes patients fail to respond to incretin therapies.
Read more